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ABSTRACT 
Hypertension or high blood pressure occurs when the high cardiac output exerts pressure on the arterial wall as the blood flow increases. Bi-
layer tablets are prepared with one layer of drug for immediate release while second layer designed to release drug later, either as second dose 
or in an extended release manner. Bi-layered tablet is suitable for sequential release of two drugs in combination, separate two incompatible 
substances, and also for sustained release tablet in which one layer is immediate release as initial dose and second layer is maintenance dose. 
Bilayer tablet is suitable for sequential release of two drugs in combination, separate two incompatible substances and also for sustained 
release tablet in which one Layer is immediate release as initial dose and second layer is maintenance dose. The preparation of tablets in the 
form of multi layers is used to provide systems for the administration of drugs. 
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1.INTRODUCTION: 
Hypertension or high blood pressure occurs when the high 
cardiac output exerts pressure on the arterial wall as the 
blood flow increases. The present available conventional 
dosage form used in the treatment of hypertension cannot 
produce the desired therapeutic effect for prolonged period 
of time and thus dose fluctuation and missing of dose 
chances are more.1 
 
Figure 1: Bi-layered tablet 
Bi-layer tablets are prepared with one layer of drug for 
immediate release while second layer designed to release 
drug later, either as second dose or in an extended release 
manner. Bi-layered tablet is suitable for sequential release of 
two drugs in combination, separate two incompatible 
substances, and also for sustained release tablet in which one 
layer is immediate release as initial dose and second layer is 
maintenance dose. The basic goal of therapy is to achieve a 
steady state drug in blood level for an extent period of time2. 
1.1 Advantage of Bi-layered tablets3-4 
 Bi-layered execution with optional single-layer 
conversion kit. 
 Cost is lower compared to all other oral dosage form. 
 Greatest chemical and microbial stability over all oral 
dosage form. 
 Objectionable odor and bitter taste can be masked by 
coating technique. 
 Flexible concept. 
 They are unit dosage form and offer the greatest 
capabilities of all oral dosage form for the greatest dose 
precision and the least content variability. 
 Easy to swallowing with least tendency for hang-up. 
 Suitable for large scale production. 
1.2 Disadvantage of Bi-layered tablets5,6 
 Some drugs resist compression into dense compacts, 
owing to amorphous nature, low density character, 
 Bitter tasting drugs, drugs with an objectionable odor 
or drugs that are sensitive to oxygen may require 
encapsulation or coating. 
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 Difficult to swallow in case of children and unconscious 
patients. 
 Drugs with poor wetting, slow dissolution properties, 
optimum absorption high in GIT may be difficult to 
formulate as a tablet that will still provide adequate or 
full drug bioavailability. 
1.3 Advantage of Bi-layered tablets over conventional 
tablets7: 
 Blood level of a drug can be held at consistent 
therapeutic level for improved drug deliver, accuracy, 
safety and reduce side effects. 
 Reduction of adverse effect can be accomplished by 
targeting the drug release to the absorption site as well 
as controlling the rate of release, enabling the total 
drug content to be reduced. 
 Patient convenience is improved because fewer daily 
doses are required compared to traditional systems. 
Patient compliance is enhanced leading to improved 
drug regimen efficacy. 
 Bi-layered tablets readily lend themselves to repeat 
action products; where in one layer provide initial 
dose, the other layer provide maintenance dose. 
 Separate physically or chemically incompatible 
ingredients. 
2. TYPES OF BI-LAYERED TABLET PRESS8-12 
 Single sided tablet press. 
 Double sided tablet press. 
 Bi-layered tablet press with displacement monitoring. 
2.1 Single sided tablet press: 
The single design is a single sided press with both chambers 
of the doublet feeder separated from each other. Each 
chamber is gravity or forced fed with different power, 
producing the two individual layers of tablets. When die 
passes under the feeder, it is first loaded with the first layer 
powder followed by the second layer powder. Then the 
entire tablet is compressed in one or two steps. 
2.2 Double sided tablet press: 
In most double sided tablet presses with automated 
production control use compression force to monitor and 
control tablet weight. The effective peak compression force 
exerted on each individual tablet of layer is measured by the 
control system at main compression of the layer. This 
measured peak compression force is the signal used by the 
control system to reject out of tolerance and correct the die 
fill depth when required. 
2.3 Bi-layered tablet press with displacement 
monitoring: 
The displacement tablet weight control principle is 
fundamentally different from the principle based upon 
compression force. When measuring displacement, the 
control system sensitivity does not depend on the tablet 
weight but depends on the applied pre-compression force.
 
 
Figure 2: Stages of Bi-layered tablet manufacturing 
 
3. ANTI-HYPERTENSIVE DRUGS WITH BRAND 
NAME13: 
 Enalapril (Vasotec) 
 Captopril (Capoten) 
 Lisinopril (Zestril and Prinivil) 
 Benazepril (Lotensin) 
 Quinapril (Accupril) 
 Perindopril (Aceon) 
 Ramipril (Altace) 
 Trandolapril (Mavik) 
 
4. PRE-FORMULATION STUDIES: 
Pre-formulation testing is the first step in rational 
development of dosage forms of a drug substance. Pre-
formulation study is the process of optimizing the delivery of 
drug through determination of physicochemical properties 
of the excipients that could affect drug performance and 
development of as efficacious, stable and safe dosage form. It 
provides a framework for the drug combination with 
pharmaceutical excipients in the dosage form. 
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4.1 Determination of λmax14 
APIs was dissolved in solvent further diluted with the same 
and scanned for maximum absorbance in UV Visible 
spectrophotometer.  
4.2 Solubility15 
The solubility of APIs was determined in distilled water, 
methanol, ethanol, acetone, chloroform and pH 6.8 
phosphate buffer by shake flask method. Absorbance is 
measured by UV-Visible Spectrophotometer. The drug 
content is calculated by using the standard graph. 
4.3 Melting point15 
Melting point of the APIs was determined by capillary 
method in triplicate. 
4.4 Standard Curve for APIs15 
100 mg of APIs was accurately weighted and dissolved in 
100 ml of solvent  to prepare first stock solution. 10 ml of 
above solution was taken and diluted to 100 ml with the 
same solvent to prepare II stock solution. The aliquot 
amount of II stock solution was further diluted to get 5, 10, 
15, 20, 25 and 30 g of drug per ml of the final solution. Then 
the absorbance was measured in a UV spectrophotometer. 
4.3.5 Compatibility studies15 
The compatibility studies of the drug with polymers are 
studies using FT-IR spectroscopy. 
FT-IR Spectroscopy16 
FT-IR spectroscopy was carried out to check the 
compatibility between drug and excipients. Infrared 
spectroscopy was conducted using s thermo Nicolet FTIR 
and the spectrum was recorded in the region of 4000 to 400 
cm-1. The sample (drug and drug-excipient mixture in 1:1 
ratio) in KBr (200-400mg) was compressed in to discs by 
applying a pressure of 5 tons for 5 min in hydraulic press. 
The interaction between drug-excipients was observed from 
IR-spectral studies by observing any shift in peaks of drug in 
the spectrum of physical mixture of drug-excipients. 
DSC Analysis for formulation17 
Thermal properties of the pure drug and the physical 
mixture of drug and excipients were analyzed by Different 
Scanning Calorimeter. The samples were heated in a 
thermetically sealed aluminium pans. Heat runs for each 
sample were set from 25 to 350 °C at a heating rate of 10 °C / 
min, using nitrogen as blanket gas. 
5. PARAMETER CONSIDER DURING FORMULATION 
DESIGN: 
5.1 Calculation of dose18 
The total dose of   APIs for once daily formulation was 
calculated by the following equation, using available 
pharmacological data. 
Dt = Dose (1 + 0.693 x t / t1/2) 
Where, Dt = Total dose of drug, 
Dose = Dose of immediate release part. 
t = Time in hr during which the sustained release is desired  
t1/2 = Half life of the drug  
 
 
5.2 Formulation of Immediate release layer19: 
Table 1: Formulation of Immediate Release Layer (IRL) 
S. No. Ingredients 
1 APIs 
2 Lactose 
3 Croscarmellose sodium 
4 Sodium starch glycolate 
5 Microcrystalline cellulose 
6 Ponceau 4R 
7 Magnesium stearate 
8 Talc 
9 Total 
 
5.3 Formulation of sustained released layer19 
Table 2: Formulation of Sustained Release Layer (SRL) 
S. No. Ingredients 
1 APIs 
2 Lactose 
3 HPMC K4M 
4 HPMC K100M 
5 Microcrystalline cellulose 
6 Magnesium stearate 
7 Talc 
8 Total 
 
5.4 Preparation of IRL20: 
IRL of APIs was prepared by wet granulation by using 
different Superdisintegrants such as SSG and Croscarmellose 
sodium. PVP K30 solution with containing coloring agent 
was used as binding solution. As DS was oily in 
characteristics, MCC was used as adsorbent. Manufacturing 
steps-Pass all the ingredients though sieve #80. Mix APIs 
with MCC geometrically and then mix with lactose. Add 
Superdisintegrants and mix for 10 to 15 min in mortar and 
pestle. Make wet mass using binding agent PVP K 30 solution 
containing color. Pass the cohesive mass through sieve # 16 
to get uniform granules. Dry the granules at 500C for 15 min 
in hot air oven. Lubricate the granules with lubricating agent 
and compressed into 250 mg each tablet weight by adjusting 
hardness.  
5.5 Preparation of SRL20: 
Accurately weighed APIs and polymer and others ingredients 
were taken in mortar and pestle and mixed well. The powder 
were mixed with sufficient quantity for PVP K30 solution 
until wet mass formed. The cohesive mass obtained was 
passed though sieve # 16 and the granules were dried in a 
hot air oven at 500C for 20 min. The dried granules again 
passed through sieve # 22 to break the large lumps. Then 
granules were mixed with talc and magnesium stearate and 
compressed into 300 mg each tablet by adjusting hardness.  
5.6 Preparation of bi-layered tablet20,21: 
By the study of disintegration and drug release profile of IRL 
and SRL, best formulations of each layer were chosen and bi-
layered tablet were prepared by double compression in 
single rotatory tableting machine. 
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6. EVALUATION OF PRE-FORMULATION 
PARAMETERS: 
6.1 Angle of Repose22 
The angle of repose of granules was determined by 
the funnel method. The accurately weighed granules were 
taken in a funnel. The height of the funnel was adjusted in 
such a way that the tip of the funnel just touched the apex of 
the heap of the granules. The granules were allowed to flow 
through the funnel greely onto the surface. The diameter of 
the powder cone was measured and angle of repose was 
calculated using equation. 
       
h
 
 
Whe e,      he   gle of  epose, h = height of the heap of the 
powder, r = radius of the heap of the powder 
Table 3: Angle of Repose 
S. No Angle of Repose (θ) Type of flow 
1 ˂ 25 Excellent 
2 25-30 Good 
3 30-40 Passable 
4 ˃ 40 Very poor 
 
6.2 Determination of bulk density and tapped density23 
A quantity of 2 g of the powder (W) from each formula was 
introduced into a 25 ml measuring cylinder. After the initial 
volume was observed, the cylinder was allowed to fall under 
its own weight onto a hard surface from the height of 2.5 cm 
at 2 sec intervals. The tapping was continued until no further 
change in volume was noted. The bulk density, and tapped 
density were calculated using following formulas. LBD and 
TDB were calculated using the following equations.  
BD= Weight of the powder blend/Untapped Volume of the 
packing BD=Weight of the powder blend/Tapped Volume of 
the packing 
6.3 Carr’s Index / Compressibility Index24 
It helps in measuring the force required to break 
the friction between the particles and the hopper. It is 
expressed in % and given by; 
     s    e  ( ) 
  ppe  e si     l  e si  
   ppe  e si  
     
6.4 Hausner’s Ratio25 
Hausner’s ratio is a indirect index of ease of powder flow. 
Hausner’s ratio was measured by the ratio of tapped density 
to bulk density. 
  
  
  
 
Whe e ρ      ppe   e si  , ρ  = bulk density 
Table 4: Scale of flowability 
Flow Character 
Compressibility 
Index (%) 
Hausner’s Ratio 
Excellent < 10 1.00 – 1.11 
Good 11 – 15 1.12 – 1.18 
Fair 16 – 20 1.19 – 1.25 
Passable 21 – 25 1.26 – 1.34 
Poor 26 – 31 1.35 – 1.45 
Very poor 32 – 37 1.46 – 1.59 
Extremely poor > 38 > 1.60 
 
7. EVALUATION OF PREPARED FORMULATIONS: 
7.1 Evaluation of APIS, IRL, SRL and Bi-Layered tablet26-
29: 
The tablets prepared were evaluated for the following 
parameters: 
 Weight variation 
 Hardness 
 Friability 
 Drug content 
 In-vitro Dissolution Studies 
7.1.1 Weight Variation Test: 
To study weight variation, 20 tablets of each formulation 
were weighted using electronic balance and the test was 
performed according to the official method. 
Table 5: Scale of flowability 
S. No. 
Average Weight of 
Tablet (mg) 
% of Deviation 
1 < 80 10 
2 < 80 – 250 7.5 
3 ≥ 250 5 
 
7.1.2 Hardness: 
The resistance of tablets to shipping or breakage under 
condition of storage, transportation and handling before 
usage depends on its hardness. The hardness of each batch of 
tablet was checked by using Monsanto hardness tester. The 
hardness was measured in the terms of kg/cm2. 5 tablets 
were chosen randomly and tested for hardness. The average 
hardness of 5 determinations was recorded. 
7.1.3 Friability: 
Friability generally refers to loss in weight of tablets in the 
containers due to removal of fines from the tablet surface. 
Friability generally reflects poor cohesion of tablet 
ingredients. 10 tablets were weighed and the initial weight of 
these tablets was recorded and placed in Roche friabilator 
and rotated at the speed of 25 rpm for 100 revolutions. Then 
tablets were removed from the friabilator dusted off the 
fines and again weighed and the weight was recorded. 
Percentage friability was calculated by using the formula. 
   ria ilit    
Initital eight    inal eight
 eight Initial
      
7.1.4 Tablet thickness: 
Thickness of the tablet is important for uniformity of tablet 
size. Thickness was measured using Vernier Calipers. It was 
determined by checking the thickness of ten tablets of each 
formulation. Vernier caliper consists of metric and imperial 
scales. The main matric scale is read first then read 
“hundredths of mm” of imperial scale (count the number of 
division until the lines concedes with the main metric scale. 
The imperial scale number is multiply with 0.02. Then that 
number obtained from imperial scale added with main 
metric scale to get final measurement. 
7.1.5 In Vitro dissolution studies: 
The release rate of tablet (n=3) was determined using The 
United States Pharmacopoeia (USP) XXIV dissolution testing 
apparatus II (paddle method). The dissolution test was 
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performed using 900 ml of 0.1 N HCl, at 37  0.5C and 75 
rpm. 
8. CONCLUSION: 
Bilayer tablet is improved beneficial technology to overcome 
the shortcoming of the single layered tablet. There is various 
application of the bi-layer tablet it consist of monolithic 
partially coated or multilayered Matrices. Bilayer tablet is 
suitable for sequential release of two drugs in combination, 
separate two incompatible substances and also for sustained 
release tablet in which one Layer is immediate release as 
initial dose and second layer is maintenance dose. The 
preparation of tablets in the form of multi layers is used to 
provide systems for the administration of drugs, which are 
incompatible and to provide controlled release tablet 
preparations by providing surrounding or multiple swelling 
layers. Bilayer tablet quality and GMP-requirements can vary 
widely. 
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